2cureX announces commercial collaboration with Gibson Oncology, USA
2cureX AB (“2cureX”) is pleased to announce that the company has established a commercial collaboration with the US based drug discovery company Gibson Oncology LLC (“Gibson Oncology”). 2cureX will use its IndiTreat® technology to stratify colorectal cancer (CRC) patients for sensitivity to the anti-cancer drug LMP400. After testing in nine CRC patient samples, 2cureX has shown that the IndiTreat® technology can stratify patients based on LMP400 sensitivity. Gibson Oncology plans to launch a phase II trial in metastatic colorectal cancer (mCRC) in Denmark in 2019. 2cureX and Gibson Oncology